313 related articles for article (PubMed ID: 15367698)
1. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
[TBL] [Abstract][Full Text] [Related]
3. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
4. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract][Full Text] [Related]
6. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Taguchi F; Koh Y; Koizumi F; Tamura T; Saijo N; Nishio K
Cancer Sci; 2004 Dec; 95(12):984-9. PubMed ID: 15596048
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Shibuya K; Komaki R; Shintani T; Itasaka S; Ryan A; Jürgensmeier JM; Milas L; Ang K; Herbst RS; O'Reilly MS
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1534-43. PubMed ID: 17889445
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
[TBL] [Abstract][Full Text] [Related]
12. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.
Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M
Cancer Biol Ther; 2010 Apr; 9(8):592-603. PubMed ID: 20139705
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
14. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
15. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
[TBL] [Abstract][Full Text] [Related]
16. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
[TBL] [Abstract][Full Text] [Related]
17. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.
Xiao X; Wu J; Zhu X; Zhao P; Zhou J; Liu QQ; Zheng L; Zeng M; Liu R; Huang W
Int J Cancer; 2007 Nov; 121(9):2095-2104. PubMed ID: 17631646
[TBL] [Abstract][Full Text] [Related]
18. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Ogino H; Yano S; Kakiuchi S; Yamada T; Ikuta K; Nakataki E; Goto H; Hanibuchi M; Nishioka Y; Ryan A; Sone S
Cancer Lett; 2008 Jun; 265(1):55-66. PubMed ID: 18364248
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
[TBL] [Abstract][Full Text] [Related]
20. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
